Evidence map›Paper›PMID 26689330›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2016

Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis.

Louise Tzung-Harn Hsieh, Helena Frey, Madalina-Viviana Nastase, Claudia Tredup, Adrian Hoffmann, Chiara Poluzzi, Jinyang Zeng-Brouwers, Tina Manon-Jensen, Katrin Schröder, Ralf P Brandes and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Matrix proteoglycans in tumor inflammation and immunity.American journal of physiology. Cell physiology · 2022
    Review
  9. Proteoglycans in Toll-like receptor responses and innate immunity.American journal of physiology. Cell physiology · 2022
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Communications via the Small Leucine-rich Proteoglycans: Molecular Specificity in Inflammation and Autoimmune Diseases.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Louise Tzung-Harn HsiehPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Helena FreyPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Madalina-Viviana NastasePharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany; Department of Pharmacology, National Institute for Chemical-Pharmaceutical Research and Development, 112 Vitan Avenue, Bucharest, Romania.
Claudia TredupPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Adrian HoffmannPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Chiara PoluzziPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Jinyang Zeng-BrouwersPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Tina Manon-JensenPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Katrin SchröderInstitut für Kardiovaskulare Physiologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Ralf P BrandesInstitut für Kardiovaskulare Physiologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.
Renato V IozzoDepartment of Pathology, Anatomy and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
Liliana SchaeferPharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany. Electronic address: schaefer@med.uni-frankfurt.de.
Goethe University Frankfurt · DESidney Kimmel Cancer Center · US

Funding

NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
NCI NIH HHS CA39481NCI NIH HHS NIH CA47282NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282
6 · The paper itself

Abstract

Biglycan, a ubiquitous proteoglycan, acts as a danger signal when released from the extracellular matrix. As such, biglycan triggers the synthesis and maturation of interleukin-1β (IL-1β) in a Toll-like receptor (TLR) 2-, TLR4-, and reactive oxygen species (ROS)-dependent manner. Here, we discovered that biglycan autonomously regulates the balance in IL-1β production in vitro and in vivo by modulating expression, activity and stability of NADPH oxidase (NOX) 1, 2 and 4 enzymes via different TLR pathways. In primary murine macrophages, biglycan triggered NOX1/4-mediated ROS generation, thereby enhancing IL-1β expression. Surprisingly, biglycan inhibited IL-1β due to enhancement of NOX2 synthesis and activation, by selectively interacting with TLR4. Synthesis of NOX2 was mediated by adaptor molecule Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF). Via myeloid differentiation primary response protein (MyD88) as well as Rac1 activation and Erk phosphorylation, biglycan triggered translocation of the cytosolic NOX2 subunit p47(phox) to the plasma membrane, an obligatory step for NOX2 activation. In contrast, by engaging TLR2, soluble biglycan stimulated the expression of heat shock protein (HSP) 70, which bound to NOX2, and consequently impaired the inhibitory function of NOX2 on IL-1β expression. Notably, a genetic background lacking biglycan reduced HSP70 expression, rescued the enhanced renal IL-1β production and improved kidney function of Nox2(-/y) mice in a model of renal ischemia reperfusion injury. Here, we provide a novel mechanism where the danger molecule biglycan influences NOX2 synthesis and activation via different TLR pathways, thereby regulating inflammation severity. Thus, selective inhibition of biglycan-TLR2 or biglycan-TLR4 signaling could be a novel therapeutic approach in ROS-mediated inflammatory diseases.

Indexed as

AnimalsBiglycanCells, CulturedInterleukin-8KidneyMacrophagesMembrane GlycoproteinsMiceNADH, NADPH OxidoreductasesNADPH Oxidase 1NADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesReperfusion InjurySignal TransductionToll-Like ReceptorsBGN protein, humanBiglycanCybb protein, mouseInterleukin-8Membrane GlycoproteinsNADH, NADPH OxidoreductasesNADPH Oxidase 1NADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesNOX1 protein, mouseNox4 protein, mouseToll-Like ReceptorsExtracellular matrixInflammationReactive oxygen species (ROS)Small leucine-rich proteoglycanToll-like receptor

Identifiers

PMID26689330
PMCPMC6953411
OpenAlexW2204828586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.